Linked CIViC Profile: FLT3 TYROSINE KINASE DOMAIN
Evidence Level Distribution
Level A: 3Level B: 34Level C: 6Level D: 35
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| B | Prognostic | Supports | Poor Outcome | Acute Myeloid Leukemia | 5 | |
| B | Prognostic | Supports | Poor Outcome | Acute Myeloid Leukemia | 5 | |
| D | Predictive | Supports | Sensitivity/Response | Acute Myeloid Leukemia | Ponatinib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Acute Myeloid Leukemia | Gilteritinib | 5 |
| B | Prognostic | Does Not Support | Acute Myeloid Leukemia | 4 | ||
| B | Prognostic | Supports | Poor Outcome | Acute Myeloid Leukemia | 4 | |
| B | Prognostic | Does Not Support | Acute Myeloid Leukemia | 4 | ||
| B | Prognostic | Supports | Poor Outcome | Acute Myeloid Leukemia | 4 | |
| B | Prognostic | Supports | Poor Outcome | Acute Myeloid Leukemia | 4 | |
| B | Prognostic | Supports | Poor Outcome | Acute Myeloid Leukemia | 4 | |
| B | Prognostic | Supports | Poor Outcome | Acute Myeloid Leukemia | 4 | |
| C | Predictive | Supports | Resistance | Acute Myeloid Leukemia | Sorafenib | 4 |
| B | Predictive | Supports | Resistance | Acute Myeloid Leukemia | Sorafenib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Acute Myeloid Leukemia | Lestaurtinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Acute Myeloid Leukemia | Sorafenib | 4 |
| D | Predictive | Supports | Sensitivity/Response | Acute Myeloid Leukemia | Tyrphostin AG 1296 | 4 |
| B | Prognostic | Supports | Poor Outcome | Acute Myeloid Leukemia | 4 | |
| B | Prognostic | Supports | Poor Outcome | Acute Myeloid Leukemia | 4 | |
| B | Predictive | Supports | Resistance | Acute Myeloid Leukemia | Quizartinib,Sorafenib | 4 |
| B | Predictive | Supports | Resistance | Acute Myeloid Leukemia | Sorafenib | 4 |